Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03277547 · ClinicalTrials.gov registry record
Kidney Function in Sickle Cell Anemia
A clinical trial of Sickle Cell Disease and Kidney Failure, Chronic, sponsored by Kenneth Ataga MD.
- Active
- Registry status
- 300
- Enrollment target
- 3
- Study locations
NCT03277547: Active study of Sickle Cell Disease and Kidney Failure, Chronic, sponsored by Kenneth Ataga MD.
NCT03277547 is a study of Sickle Cell Disease and Kidney Failure, Chronic that is active but no longer recruiting, run by Kenneth Ataga MD. The registered enrollment target is 300 participants, roughly in line with the 291-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target. The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03277547, a study of Sickle Cell Disease and Kidney Failure, Chronic, is active but no longer recruiting, sponsored by Kenneth Ataga MD.
- ACTIVE NOT RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a prospective clinical cohort study that involves a baseline study visit followed by up to 3 annual follow-up study visits for a total follow-up of 36-48 months to evaluate the age- and sex-adjusted rate of change in kidney function, and to identify biomarkers of endothelial function, metabolomic profiles and clinical characteristics for the worsening of kidney function and for a rapid decline in kidney function. "Funding Source - FDA OOPD"
Primary Outcome
Estimated glomerular filtration rate will be ascertained using the CKD EPI equation
Conditions Studied
Study Locations (3)
North Carolina
- University of North Carolina-Chapel Hill - Chapel Hill
Ohio
- Ohio State Adult Sickle Cell Program - Columbus
Tennessee
- UTHSC Center for Sickle Cell Disease - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2017-11-17 |
| Est. Completion | 2025-12-01 |
What the registry record for NCT03277547 still lists
NCT03277547 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 291-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target.
The record links to 2 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 0 interventions.
NCT03277547 reports a single indexed study location in North Carolina, Ohio, Tennessee.
Frequently Asked Questions
What is clinical trial NCT03277547 about?
NCT03277547 is a clinical study titled "Kidney Function in Sickle Cell Anemia". This is a prospective clinical cohort study that involves a baseline study visit followed by up to 3 annual follow-up study visits for a total follow-up of 36-48 months to evaluate the age- and sex-adjusted rate of change in kidney function, and to identify biomarkers of endothelial function, metabo...
What is the current status of trial NCT03277547?
This trial is currently active not recruiting. The enrollment target is 300 participants. The study started on 2017-11-17. Estimated completion is 2025-12-01.
What conditions does trial NCT03277547 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Kidney Failure, Chronic.
Who is sponsoring clinical trial NCT03277547?
This trial is sponsored by Kenneth Ataga MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03277547 being conducted?
This trial has 3 study locations across North Carolina, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03277547's enrollment target sits among peer trials
300 19th of 213 higher than 194 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Early Life Exposures Among Children With Sickle Cell Disease
RECRUITING · NA
-
Exercise in Child Health
RECRUITING · NA
-
Sickle Cell Children's Exercise Study (SuCCESs)
RECRUITING · NA
-
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
RECRUITING · Phase 1
-
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI